Skip to main content

Table 4 Results: Cost-effectiveness of HPV-vaccination in Denmark including protection against genital cancer and head & neck cancer

From: Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females

 

Average incremental vaccination costs per year (€, PV)

Average savings in treatment costs per year (€, PV)

Average incremental cost per year (€, PV)

Average LYG (PV)

Average QALYs gained (PV)

ICER (€/LYG)

ICER (€/QALY)

Average number of cases avoided per year

Vaccinations of girls vs. screening alone:

        

Base case result*

11,504,613

9,480,325

2,024,288

528.5

565.3

3,830

3,581

 

  Cervical cancer

       

197

  Anogenital cancer

       

80

  Head and neck cancer

       

43

Univariate sensitivity analysis:

        

Discount rate 0%

11,504,613

19,622,317

- 8,117,704

1,706.5

1,645.5

Dominance

Dominance

 

Discount rate 5%

11,504,613

6,603,582

4,901,031

265.3

312.5

18,476

15,682

 

Costs discounted with 3% and LYG & QALYs with 0%

11,504,613

9,480,325

2,024,288

1,706.5

1,645.5

1,186

1,230

 

Vaccine price reduced by 25%

8,967,267

9,480,325

−513,058

528.5

565.3

Dominance

Dominance

 

2-dose regime

8,121,485

9,480,325

−1,358,840

528.5

565.3

Dominance

Dominance

 

Treatment cost reduced by 25%

11,504,613

7,055,464

4,449,149

528.5

565.3

8,418

7,870

 

Time horizon 40 years

11,504,613

8,450,127

3,054,486

425.2

472.2

7,184

6,469

 

Bivalent HPV vaccination (HPV types 16 & 18)

11,504,613

5,269,690

6,234,923

528.5

505.1

11,797

12,345

 

Protection against head and neck cancer excluded:

11,504,613

9,159,308

2,345,305

432.1

470.4

5,428

4,985

 

 70% vaccination rate

9,474,387

9,320,914

153,473

489.2

551.9

314

278

 

  Cervical cancer

       

192

  Anogenital cancer

       

77

  Head and neck cancer

       

42

Vaccination of girls & boys vs. girls:

        

Base case result**

11,858,601

1,186,760

10,671,841

263

256

40,615

41,636

 

  Cervical cancer

       

5

  Anogenital cancer

       

34

  Head and neck cancer

       

98

Univariate sensitivity analysis:

        

Discount rate 0%

11,858,601

4,298,652

7,559,950

889

863

8,500

8,763

 

Discount rate 5%

11,858,601

587,457

11,271,144

124

122

90,704

92,015

 

Vaccine price reduced by 25%

9,243,183

1,186,760

8,056,423

263

256

30,661

31,432

 

2-dose regime

8,371,377

1,186,760

7,184,617

263

256

27,343

28,031

 

Time horizon 40 years

11,858,601

1,194,383

10,664,218

239

225

44,674

47,342

 

Protection against head and neck cancer excluded

1,858,601

459,212

11,399,389

42

41

269,857

276,642

 

70% vaccination rate

9,765,907

1,281,863

8,484,044

301

268

28,146

31,615

 
  1. 2008 price level.
  2. *Vaccination over 62 years (implying that the incremental costs and effects are calculated as an average over the 62 years, assuming vaccination from the first year and onward) of 12-year-old girls compared to screening alone, 85% vaccination rate, discount rate 3%, 100% vaccine efficacy, vaccine price: € 123 per dose ex. VAT (=market price, source www.promedicin.dk, 10th of May, 2012).
  3. **Vaccination over 62 years of 12-year-old girls and boys compared to 12-year-old girls alone, 85% vaccination rate, discount rate 3%, 100% vaccine efficacy, vaccine price: € 123 per dose ex. VAT (=market price, source www.promedicin.dk, 10th of May, 2012).
  4. PV: present value; QALY: quality-adjusted life-year; ICER: incremental cost-effectiveness ratio; LYG: life-year gained.
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us